Dupixent’s FDA Approval for COPD: What to Know

Dupixent (dupilumab) became the first biologic therapy approved by the FDA for chronic obstructive pulmonary disease in September 2024, marking a significant shift in how the disease can be treated. The approval applies specifically to adults with inadequately controlled COPD who have an eosinophilic phenotype, meaning elevated blood eosinophil counts that signal a particular kind of underlying inflammation. For the roughly 300,000 to 400,000 people in the United States estimated to fit that profile, this opens a treatment avenue that goes beyond the traditional combination of inhalers and oral steroids. But who actually qualifies, how well does it work, and what should you expect if your doctor brings it up?

Why a Biologic for COPD Is a Big Deal

COPD has long been treated as a single disease with a fairly narrow toolkit: bronchodilators to open the airways, inhaled corticosteroids to dampen inflammation, and oral steroids or antibiotics when exacerbations hit. The standard “triple therapy” combines a long-acting beta-agonist, a long-acting muscarinic antagonist, and an inhaled corticosteroid (commonly abbreviated LABA + LAMA + ICS). For many people, that regimen works reasonably well. But a subset of patients keeps having flare-ups despite using all three inhalers correctly. Until now, there was essentially nothing else to offer beyond adjusting doses or adding another oral medication.

Dupixent’s approval changes the picture because it targets a specific biological pathway rather than broadly suppressing inflammation. COPD was traditionally understood as a disease driven by neutrophilic, or “type 1,” immune responses, the kind linked to smoking damage and chronic irritation. But research over the past decade has made clear that a meaningful proportion of people with COPD also have “type 2” inflammation, the same immune pathway that drives asthma, eczema, and nasal polyps.¹ Elevated blood eosinophils are the main marker that flags this subtype. Dupixent was designed to shut down that specific pathway.

How Dupixent Works

Dupilumab is a monoclonal antibody, a lab-engineered protein that locks onto a very specific target in the immune system. In this case, it binds to the IL-4 receptor alpha subunit, a shared docking station used by two inflammatory signaling molecules called IL-4 and IL-13.² By blocking that receptor, Dupixent prevents both IL-4 and IL-13 from delivering their signals, which in turn dials down the cascade of type 2 inflammation.³

This dual blockade matters because IL-4 and IL-13 each play overlapping but distinct roles. IL-4 is heavily involved in priming immune cells toward an allergic-type response, while IL-13 drives mucus overproduction and tissue remodeling in the airways. Blocking only one of the two leaves the other free to continue causing problems. The fact that dupilumab shuts down both through a single receptor target is a key part of its mechanism and helps explain why it has shown efficacy across several diseases with type 2 signatures, including asthma, atopic dermatitis, and chronic sinusitis with nasal polyps.⁴

The Clinical Evidence Behind the Approval

The FDA based its decision on two large phase 3 trials, called BOREAS and NOTUS. Both enrolled adults with moderate-to-severe COPD who were already on triple inhaled therapy and still experiencing exacerbations, and who had blood eosinophil counts of at least 300 cells per microliter.

In the BOREAS trial, patients receiving dupilumab had a roughly 30% lower rate of moderate or severe exacerbations over one year compared to placebo. The annualized exacerbation rate was about 0.78 with dupilumab versus 1.10 with placebo.⁵ Lung function also improved: the amount of air patients could force out in one second (FEV1) increased by about 160 ml with dupilumab versus 77 ml with placebo by week 12, and that gap held through week 52.⁶

The NOTUS trial confirmed those findings in an independent group of patients. The exacerbation reduction was even slightly larger, at about 34%, with an annualized rate of 0.86 on dupilumab versus 1.30 on placebo. FEV1 improved by 139 ml with dupilumab compared to 57 ml with placebo at week 12, a difference of 82 ml that remained significant at week 52.⁷ Having two independent trials reach consistent conclusions gave regulators high confidence in the results.

Additional analyses showed that the benefits held regardless of whether patients also had emphysema. Dupilumab reduced exacerbation rates by about 29% in patients with emphysema and 31% in those without, suggesting the drug works across different structural presentations of COPD.⁸ The improvements in lung function were also consistent across different levels of disease severity, as measured by a composite index that factors in body mass index, airflow obstruction, breathlessness, and exercise capacity.⁹

Who Qualifies and How Doctors Decide

The approval is not for everyone with COPD. The FDA label specifies adults with inadequately controlled COPD and an eosinophilic phenotype. In practical terms, that means you need to meet a few criteria before Dupixent becomes a real option. First, you should already be on maximized inhaled therapy, typically the triple combination of LABA + LAMA + ICS. If your symptoms and exacerbations are well controlled on inhalers alone, a biologic is not the next step. Second, your blood eosinophil count needs to be elevated. The trials used a threshold of 300 cells per microliter or higher, and this is the marker most doctors will rely on.

The 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report has already incorporated this approval, recommending dupilumab as an add-on therapy for COPD patients with eosinophilia and chronic bronchitis whose symptoms are not adequately managed by triple inhaled therapy.¹⁰ This is a meaningful signal for everyday clinical practice because GOLD guidelines are what most pulmonologists follow when making treatment decisions.

One biomarker worth understanding beyond eosinophils is fractional exhaled nitric oxide (FeNO). This is a breath test that measures airway inflammation. Some analyses of the trial data suggest that patients with higher FeNO levels, specifically 20 parts per billion or above, may get an even greater benefit from dupilumab.¹¹ Your doctor may order a FeNO test alongside blood work when deciding whether you are a good candidate.

How Dupixent Compares to Other Biologics

Dupilumab is not the only biologic that has been studied in COPD, but it is the first to earn FDA approval for the condition. Other biologics targeting eosinophilic inflammation, such as mepolizumab and benralizumab, which work by different mechanisms, have also been tested. Mepolizumab targets IL-5, a molecule that promotes eosinophil survival, while benralizumab directly depletes eosinophils by targeting the IL-5 receptor. Both have been approved for severe eosinophilic asthma, and mepolizumab was recently approved for COPD in some countries as well.

A systematic review and network meta-analysis comparing biologics in COPD found that dupilumab was the most effective at reducing exacerbations, with high-certainty evidence showing a 32% reduction relative to placebo. The same analysis found that dupilumab probably reduced exacerbations more than mepolizumab did, with moderate certainty. Benralizumab and newer agents like itepekimab and tezepelumab showed smaller or less certain benefits.¹²

A separate head-to-head analysis comparing dupilumab and mepolizumab trial data found that while both drugs reduced exacerbation rates to a similar degree, dupilumab offered broader benefits. Dupilumab showed improvements in quality of life, daily symptoms, and lung function on top of exacerbation reduction, whereas mepolizumab did not demonstrate significant gains in those areas.¹¹ Reviews of the overall landscape have concluded that dupilumab provides the most consistent benefit among available biologics for eosinophilic COPD.¹³

Safety and Side Effects

Across the BOREAS and NOTUS trials, the rate of side effects with dupilumab was broadly similar to placebo. Pooled analysis showed that treatment-emergent adverse events, serious adverse events, events leading to treatment discontinuation, and deaths were comparable between the two groups.¹⁴ That safety profile is reassuring, though it comes with the usual caveat that clinical trial populations are carefully selected and real-world experience may surface rarer issues over time.

Dupilumab has already accumulated years of real-world safety data from its other approved uses, including atopic dermatitis (approved since 2017) and asthma. The most commonly reported side effects across those indications include injection-site reactions, conjunctivitis (more common in dermatitis patients), and temporarily elevated eosinophil counts soon after starting treatment. In a seven-year population-based cohort study of COPD patients who received dupilumab, the drug was associated with lower all-cause mortality, fewer emergency department visits, lower rates of subsequent pneumonia, and even reduced rates of new-onset heart failure and anxiety compared to non-users.¹⁵ Observational data like this is encouraging, though it can be influenced by selection bias since the patients who receive a biologic may differ from those who do not in ways that affect outcomes independently.

Reducing the Need for Oral Steroids

One of the more practical benefits of dupilumab for people with frequent COPD flare-ups is the potential to cut down on systemic corticosteroid courses. Prednisone and similar oral steroids are the mainstay treatment for COPD exacerbations, but repeated use carries serious long-term risks, including bone loss, diabetes, weight gain, and immune suppression. A pooled analysis of the BOREAS and NOTUS data found that among patients who had severe exacerbations, dupilumab reduced systemic corticosteroid use by about 42% compared to placebo. For moderate exacerbations, the reduction was about 28%.¹⁶

For someone who has been through three or four steroid bursts a year, that reduction is not trivial. The accumulated damage from repeated courses of oral steroids is one of the more insidious aspects of poorly controlled COPD, and any strategy that meaningfully lowers steroid exposure while keeping exacerbations in check has real downstream health benefits.

Quality of Life and Day-to-Day Symptoms

Beyond exacerbation counts and spirometry numbers, the trials measured how patients actually felt. Using the St George’s Respiratory Questionnaire (SGRQ), a well-validated tool for assessing respiratory quality of life, pooled data from both trials showed that dupilumab-treated patients had greater improvements in symptoms, activity limitations, and overall impact on daily life at week 52 compared to placebo. Breathlessness, cough, and sputum scores all improved, as did a separate daily symptom diary measure (the E-RS:COPD).¹⁷

These quality-of-life gains distinguish dupilumab from some other biologics studied in COPD. As noted earlier, mepolizumab reduced exacerbations but did not consistently improve symptom scores or lung function in COPD trials. The fact that dupilumab moved the needle on daily symptoms and not just flare-up frequency gives it a more complete clinical profile.

Practical Considerations for Patients

Dupixent is given as a subcutaneous injection, typically every two weeks. Most patients learn to self-inject at home using either a pre-filled syringe or a pre-filled pen. In a study of patients with severe allergic diseases using dupilumab, about 86% successfully self-injected, and roughly 71% consistently adhered to the scheduled injection dates. Adherence tended to decrease somewhat with longer treatment duration. The pre-filled pen scored higher on usability and patient satisfaction, though it caused slightly more pain during injection than the traditional syringe.¹⁸

Cost is a significant hurdle. In the United States, the list price of Dupixent is roughly $3,000 to $3,500 per month before insurance. Most patients with commercial insurance or Medicare pay far less through manufacturer copay assistance programs, though coverage decisions by individual insurers are still being worked out for the new COPD indication. Prior authorization is nearly universal, meaning your doctor will need to document that you meet specific criteria before the insurer approves it. A cost-effectiveness analysis from Colombia found that at current pricing, dupilumab was not cost-effective in that country’s healthcare system unless the drug price dropped substantially.¹⁹ Pricing and access will look very different depending on where you live and what coverage you have.

What About People With Overlapping Conditions

Many patients with COPD also have asthma, a condition known as asthma-COPD overlap, or features of atopic dermatitis or chronic sinusitis with nasal polyps. Because dupilumab is already approved for all three of those conditions individually, it can function as a single biologic addressing multiple related diseases driven by the same type 2 inflammatory pathway.²⁰ If you have COPD with elevated eosinophils and you also suffer from uncontrolled eczema or chronic sinus disease, dupilumab may improve all of those conditions simultaneously.

Early research on asthma-COPD overlap specifically suggests that dupilumab may improve lung function and exercise tolerance in this population, along with measurable changes to airway structure on imaging.²¹ This is still a developing area, but it highlights one of the practical advantages of a biologic that targets a broad upstream pathway rather than a single molecule downstream.

What Dupixent Does Not Do

It is worth being clear about the limits. Dupixent does not cure COPD, and it does not replace your inhalers. The trials specifically added dupilumab on top of maximized triple inhaled therapy, so the benefits you see in the data are on top of what inhalers were already providing. If you stop your inhalers after starting Dupixent, you would likely get worse, not better.

Dupixent also does not help every type of COPD. If your eosinophils are not elevated, the drug is unlikely to benefit you, and it is not approved for that population. The same applies to patients whose COPD is primarily driven by neutrophilic inflammation or structural damage from decades of smoking. Biologics targeting non-type-2 pathways and alarmin pathways have so far yielded limited or inconsistent results in COPD, underscoring that improved methods for identifying which patients will respond to which treatments remain an unmet need.²²

The lung function gains, while statistically significant and sustained, are also modest in absolute terms. An 80-to-83 ml improvement in FEV1 over placebo is meaningful for someone whose breathing is already severely compromised, but it is not the kind of dramatic improvement that makes COPD feel like it has gone away. The real value shows up more in the reduction of exacerbations, which are the events that send people to the hospital, erode lung function over time, and carry genuine mortality risk. If you think of Dupixent as an exacerbation-prevention strategy rather than a breathing cure, the expectations will line up better with the evidence.